Covance (Princeton, NJ) is increasing its capacity to support specialized sleep studies through a new collaboration with Sleep Medicine Associates. The collaboration gives Covance access to Sleep Medicine Associates’ eight-bed, state-of-the art research facility in Evansville, IN, along with specialized support for studies in restless leg syndrome, insomnia, narcolepsy, fibromyalgia, and other conditions related to the central nervous system.
Covance reports that Board certified sleep expert David Cocanower, MD, of Sleep Medicine Associates, will provide specialized sleep and neurological monitoring and will consult on sleep-specific protocols and study design.
“We are excited to expand our sleep therapeutic expertise, capacity, and recruitment capabilities to better support client needs in this highly specialized area,” said Randall Stoltz, M.D., CPI, medical director, Covance. “Sleep Medicine Associates adds industry-leading expertise and cutting edge technology to Covance’s portfolio.”
Sleep Medicine Associates is fully accredited by the American Academy of Sleep Medicine.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.